Navigation Links
Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy
Date:7/11/2014

MISSISSAUGA, ON, July 11, 2014 /CNW/ - Sunovion Pharmaceuticals Canada Inc. (Sunovion) today announced that Health Canada approved APTIOMTM (eslicarbazepine acetate) for use as a once-daily adjunctive therapy for the treatment of partial-onset seizures in patients with epilepsy who are not satisfactorily controlled with conventional therapy.  APTIOMTM is not indicated for use in patients under 18 years of age.

Epilepsy is one of the most common neurological disorders and according to Epilepsy Canada, it affects 0.6% of the population and each year approximately 15,500 people learn they have epilepsy.  Partial-onset seizures are the most prevalent seizure type, accounting for 60% of new epilepsy diagnoses1 and approximately one third of patients do not have adequate seizure control5.

The approval of APTIOMTM is based on three Phase 3 randomized, double-blind, placebo-controlled, safety and efficacy trials (Studies BIA-2093-301, BIA-2093-302 and BIA-2093-304), which included more than 1,400 people living with partial-onset seizures inadequately controlled by one to three concomitant AEDs (including carbamazepine, lamotrigine, valproic acid and levetiracetam). In these global studies,  treatment with APTIOMTM demonstrated statistically significant reductions in standardized seizure frequency versus placebo, and significantly more APTIOMTM treated patients experienced seizure frequency reduction of 50% or more from baseline (41% compared to 22% for placebo-treated patients).

The most frequently reported adverse reactions in patients taking APTIOMTM were dizziness, somnolence, headache, nausea, diplopia, vomiting, fatigue, ataxia, vision blurred, and vertigo.

"The approval of APTIOMTM is an important milestone not only for our company, but for thousands of Canadians living with, and affected by epile
'/>"/>

SOURCE Sunovion Pharmaceuticals Canada Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders
2. Collaborations, FDA Approvals, Appointments, Patents, and Stock Movements - Research Report on Aetna, United Therapeutics, Perrigo, Arena Pharmaceuticals, and Keryx Biopharmaceuticals
3. Shimadzu’s New Aggregates Sizer Aggregation Analysis System for Biopharmaceuticals Enables Real-time Quantitative Analysis
4. Savient Receives Approval From Bankruptcy Court To Sell Substantially All Assets To Crealta Pharmaceuticals
5. Biotech Briefing: Advancing Biotechs Forging Ahead With Breaking News Developments: Alliqua, OncoMed Pharmaceuticals, EnteroMedics, Unilife, Amarin
6. Vanda Pharmaceuticals to Present at the 25th Annual Piper Jaffray Healthcare Conference
7. Actinium Pharmaceuticals Announces 2013 Annual Shareholder Meeting
8. Avanir Pharmaceuticals to Participate in Two Conferences in December
9. Jazz Pharmaceuticals Announces Participation at the Piper Jaffray Healthcare Conference on December 3
10. RXi Pharmaceuticals Reports Financial Results for the Third Quarter of 2013
11. RXi Pharmaceuticals Announces the Start of Their First Phase 2 Study with RXI-109 for Treatment of Hypertrophic Scars in Conjunction with Scar Revision Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... China , 22 juli 2014 BGI ... BGI, ,s wereld grootste organisatie op het gebied van ... service ten behoeve van hele menselijke genoomsequentie via het ... In 2013 acquireerde BGI Complete Genomics, ... staat vanwege de in eigen beheer ontwikkelde sequentietechnologieën met ...
(Date:7/22/2014)... In chemical and petrochemical plants, ... sight. The rapid rise of TDL analyzers over ... as a core gas measurement technology, and their ... the gas analyzer technology of choice for many ... some processes have limited their application range. METTLER ...
(Date:7/22/2014)... Seattle, WA (PRWEB) July 22, 2014 Quorum ... a new service for large clinical trials called Quick ... and is designed to address the research industry’s need for ... The service is available for studies planning 50 or ... with a combined planned North American site count of 80 ...
(Date:7/22/2014)... Juli 2014 Qforma, ein führender Anbieter ... von Marcus Bergler zum General Manager ... europäischen kommerziellen Aktivitäten von Qforma bereits als Vice ... anschloss, war er in Positionen als VP Vertrieb ... Deutschland bei IMS Health und als Direktor bei ...
Breaking Biology Technology:BGI Tech introduceert service op gebied van hele menselijke exoomsequencing op geavanceerd Complete Genomics-platform 2METTLER TOLEDO Shows How Tunable Diode Lasers (TDLs) Can Be Installed Where No TDLs Have Gone Before 2Quorum Review IRB Launches New Quick Step™ Service for Large Clinical Trials 2Quorum Review IRB Launches New Quick Step™ Service for Large Clinical Trials 3Qforma gibt Schaffung des neuen Postens als General Manager in Europa bekannt 2
... Red Herring has announced,that ProGenTech Limited was a winner of the ... technology companies based in Asia. , ... Asia and identified the top 100 out of more than 1,000,closely ... "It is truly an honor ...
... the U.S. Patent and Trademark Office has ... for Traumatic Injury to the Nervous System”, ... University of Florida with the company as ... method of determining the presence of neural ...
... Inc.,(Nasdaq: BNVI ) will present findings on the ... Annual San Antonio Breast Cancer Symposium,being held at the Henry ... Bionovo,s poster presentation will ... BN107. As explained by Dr. Emma Shtivelman,Director of Cancer Research ...
Cached Biology Technology:Red Herring Awards ProGenTech Limited for the 2008 Red Herring Asia 100 2 Banyan Biomarkers Announces Issuance of U.S. Patent for Biomarkers for Traumatic Injury 2Bionovo to Present Recent Findings of BN107, its Anticancer Agent, at the 31st Annual San Antonio Breast Cancer Symposium 2
(Date:7/22/2014)... allergic to dust mites (and chances are you are), ... the University of Iowa have developed a vaccine that ... immune response. In animal tests, the nano-sized vaccine package ... to the allergens, according to the paper, published in ... Journal . One big reason why it works, ...
(Date:7/22/2014)... Health Policy and Economics have linked tighter Medicaid ... for schizophrenic individuals. , The study comes amid ... actually save money, when other costs are taken ... extra approval step before tests or treatments can ... prior authorization is intended to encourage physicians ...
(Date:7/22/2014)... be on the horizon. Bacteria that produce a ... insulin resistance and other adverse effects of a ... discovered., "Of course it,s hard to speculate from ... Ph.D., assistant professor of Pharmacology. "But essentially we,ve ... in mice, even though they,re eating a high-fat ...
Breaking Biology News(10 mins):Researchers create vaccine for dust-mite allergies 2Are state Medicaid policies sentencing people with mental illnesses to prison? 2Vanderbilt study shows therapeutic bacteria prevent obesity in mice 2
... lice treatments such as the pyrethroids cypermethrin and deltamethrin, ... increased from 2008 to 2009, although use of emamectine ... again due to resistance problems, e.g. azametiphos, diflubenzuron and ... 1997, was also used again in 2009, mainly under ...
... The National Foundation for Cancer Research announced today ... the Department of Molecular and Experimental Medicine at The ... of the 5th Annual Szent-Gyrgyi Prize for Progress in ... on a humble chicken virus in the early 1960s, ...
... older than previously thought, says a new analysis of the ... plants, or angiosperms, first arose 140 to 190 million years ... Proceedings of the National Academy of Sciences pushes back ... 25 to 75 million years earlier than either the fossil ...
Cached Biology News:5th Annual Szent-Györgyi Prize for Progress in Cancer Research awarded 25th Annual Szent-Györgyi Prize for Progress in Cancer Research awarded 3Molecular study could push back angiosperm origins 2Molecular study could push back angiosperm origins 3
... cDNA Library Panels were designed for full-length ... of PCRs to identify the desired cDNA ... in a 96-well "Master Plate," where each ... Having identified the positive well(s) by gel ...
... Library Panels were designed for full-length gene ... PCRs to identify the desired cDNA clone. ... a 96-well "Master Plate," where each well ... identified the positive well(s) by gel electrophoresis ...
... Technologys R.A.P.I.D. System (Ruggedized Advanced Pathogen ... PCR thermocycler designed for field hospitals, ... In addition to its ruggedness, it ... and specify as the LightCycler instrument. ...
Application: For use as a carrier in nucleic acid purification and precipitation. Physical form: Solution in 10 mM Tris HCl, pH 7.4, 1 mM EDTA Concentration: 9-11 mg/mL Physical Form: buffered aqu...
Biology Products: